CellTrans Inc
A Turning Point in Diabetes Treatment with Islet Cell Therapy
José Oberholzer, Founder and President, CMO
Diabetes Cell Therapy
Diabetes Cell Therapy is a regenerative medical approach that replaces or repairs insulin-producing pancreatic beta cells using stem cells, engineered tissues, or cellular transplants. It aims to restore endogenous insulin production, reduce dependency on external insulin, and provide long-term glycaemic control in Type 1 and advanced Type 2 diabetes patients.
Solutions
CellTrans has achieved what no other company has: FDA approval for the first-ever allogeneic islet cell therapy— Lantidra—marking a watershed moment in the treatment of diabetes.
State of Industry
Engineered Biomatrices: Transforming Science with Synthetic Serum and Urine
The increasing demand for consistent, reliable, and contaminant-free biological matrices in various scientific and industrial applications drives the manufacturing of synthetic serum and urine. These synthetic alternatives are rapidly displacing their naturally derived counterparts due to inherent advantages in reproducibility, stability, and safety, paving the way for more precise and ethical research, diagnostic, and product development endeavors.
Deep Dive
Diabetes Cell Therapys Clinical Standard
Diabetes care has entered a more demanding stage in which executives evaluating cell-based therapies must look beyond glucose monitoring systems, insulin delivery devices and incremental management improvements. For patients with brittle type 1 diabetes who continue experiencing severe hypoglycemia despite intensive treatment, the key question is no longer whether another management layer can be added. Instead, organizations must determine whether a therapy pathway can restore meaningful insulin-producing function while satisfying the clinical, regulatory and operational demands associated with advanced biotechnology programs.
Leadership Perspective
Lawrence General Hospital
Reducing Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Population
Eduardo Haddad, Chief Medical Affairs
This may appear to be intuitive to every health care provider but it is in fact an elusive goal not necessarily discussed or much less emphasized on day-to-day management of diabetes at the primary care sites.
